Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

CureVac AG. (3/16/20). "Press Release: CureVac Announces Leadership Update". Tübingen & Boston, MA.

Organisation Organisation CureVac AG
  Group CureVac (Group)
Products Product mRNA technology
  Product 2 mRNA-based vaccine
Persons Person Hoerr, Ingmar (CureVac 201806– Chairman of Supervisory Board before 2000–201806 CEO + Co-Founder)
  Person 2 Haas, Franz-Werner (CureVac 201206– Chief Corporate Officer before Sygnis + Lion BIoscience)
     


CureVac AG announced today that Ingmar Hoerr, CEO of the company, will take a temporary leave of absence for medical reasons. Ingmar Hoerr’s leave is not caused by coronavirus. CureVac’s Supervisory Board fully supports the experienced management team in place and appoints Franz-Werner Haas, Deputy CEO to assume Hoerr’s role until his return.


About CureVac AG

CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.


CureVac Media Contact

Thorsten Schüller, Head of Corporate Communications
Tel: +49 (0)7071 9883-1577
Email: thorsten.schueller@curevac.com

   
Record changed: 2020-03-20

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top